Alkermes Deal History & Licensing Activity
Alkermes is a large biotech. Over the past three years, Alkermes has been involved in 3 licensing and acquisition transactions, with a primary focus on Other (3 deals). The company currently has 11 active clinical trials, primarily in CNS Disorders.
Deals (12mo)
3
Active Trials
11
Top Modality
Other
Focus Area
CNS Disorders
Alkermes Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Alkermes in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Avadel narcolepsy/sleep medicine franchise | Avadel Pharmaceuticals | Small Molecules | Approved | acquisition | Jun 2, 2026 |
| Alutard HDM and ACARIZAX allergy immunotherapy | GenSci | Other | Approved | license | Sep 1, 2025 |
Alkermes Pipeline Focus
Therapeutic areas and modalities where Alkermes is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Alkermes Strategic Signals
Key indicators of Alkermes's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Alkermes Clinical Pipeline
Alkermes has 11 active clinical trials across 5 development phases.
1
Not Applicable
1
Phase 4
1
Unknown
3
Phase 2
5
Phase 3
See How Your Asset Matches Alkermes's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for CNS Disorders assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Alkermes Licensing & Deal Activity
Alkermes is a large biotech company that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Alkermes ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Alkermes include CNS Disorders (6 deals and trials), Immunology (3 deals and trials), and Neurology (2 deals and trials). In terms of modality, Alkermes has shown particular interest in other, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Alkermes and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Alkermes's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.